Ovid Therapeutics Announces Election of Bart Friedman to Its Board of Directors

Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, today announced that Bart Friedman has joined the Company’s Board of Directors, according to a Business Wire press release.

Mr. Friedman is a senior partner at the Wall Street law firm Cahill Gordon & Reindel LLP and is Chairman of its Business Development Committee.

Read the full press release here.